Production approval for Lorlatinib 25mg

Lorlatinib is used as a first-line treatment for patients with anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC). In the critical phase III CROWN study, for ALK positive NSCLC patients who had not received prior treatment, loratinib reduced the risk of disease progression or death by 72% compared to the clotozantinib group.